INDIANAPOLIS, Feb. 19, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has accepted the recommendation of the ACCELERATE study academic executive committee, based on emerging science in the cardiovascular field, to extend the Phase 3 trial of the investigational medicine evacetrapib by approximately six months. The decision is not based on any data from ACCELERATE, as both the academic committee and the company remain blinded to efficacy results.
Last patient visit in ACCELERATE - which is evaluating evacetrapib in approximately 12,000 people with high-risk atherosclerotic cardiovascular disease (ASCVD) -- is now expected in July 2016.
Lilly Provides Update on Evacetrapib Phase 3 Trial (NYSE:LLY)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.